Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP1 | P13497 | 1/20 | 0.41 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 6/20 | 0.35 |
| ▸ | MMP3 | P08254 | 5/20 | 0.35 |
| ▸ | MMP9 | P14780 | 5/20 | 0.35 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754362 | 0.85 | KISS1R (0.42) | BMP1KISS1RMMP9ANPEP | |
| SCHEMBL2873906 | 0.85 | — | — | |
| SCHEMBL24920452 | 0.79 | TSHR (0.44) | KISS1R | |
| SCHEMBL2872488 | 0.77 | BMP1 (0.45) | BMP1MMP1MMP3MMP9ANPEP | |
| SCHEMBL7754372 | 0.76 | KISS1R (0.40) | BMP1KISS1RMMP9ANPEP | |
| SCHEMBL7754360 | 0.76 | KISS1R (0.36) | KISS1RANPEP | |
| SCHEMBL2874729 | 0.74 | BMP1 (0.42) | BMP1KISS1RMMP1MMP3MMP9 | |
| SCHEMBL6209739 | 0.74 | BMP1 (0.42) | BMP1MMP1MMP3MMP9ANPEP | |
| SCHEMBL9814833 | 0.72 | BMP1 (0.45) | BMP1MMP1MMP3MMP9ANPEP | |
| SCHEMBL2868527 | 0.72 | FOLH1 (0.44) | BMP1MMP1MMP3MMP9FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8834842-B2 | Vitamin-targeted imaging agents | ENDOCYTE, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140065068-A1 | VITAMIN-TARGETED IMAGING AGENTS | ENDOCYTE, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065068-A1 | VITAMIN-TARGETED IMAGING AGENTS | VDR, CYP2R1, CYP24A1 | BMP1 1913/4885KISS1R 858/4885MMP1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.